ReviewTherapeutic advances in musculoskeletal disease2014
Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know.
Review in Therapeutic advances in musculoskeletal disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- What factors could influence physicians' management of women of childbearing age with chronic inflammatory disease? A systematic review of behavioural determinants of clinical inertia.BMC health services research · 2019Pooled it
- Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis.Rheumatology international · 2019Guideline
- Infectious comorbidities in pregnant patients with rheumatic diseases.Rheumatology international · 2026Review
- Deciphering the influence of pregnancy on rheumatoid arthritis and psoriatic arthritis: insights from musculoskeletal ultrasound dynamics.Archives of gynecology and obstetrics · 2025Observational
- Pregnancy outcomes of non-tumour necrosis factor inhibitor biologic disease-modifying antirheumatic drugs among individuals with autoimmune diseases: a scoping review and proposed framework for reporting outcomes.EULAR rheumatology open · 2025Article
- Diagnostic Value of Short Course Low-dose Prednisolone in Patients with Clinically Suspected Seronegative Inflammatory Arthritis - A Retrospective Study.Current rheumatology reviews · 2024Article
- Article
- Management of idiopathic intracranial hypertension in pregnancy.Obstetric medicine · 2022Review
- The positive effect of pregnancy in rheumatoid arthritis and the use of medications for the management of rheumatoid arthritis during pregnancy.Inflammopharmacology · 2021Review
- Rheumatologic Medication Use During Pregnancy.Obstetrics and gynecology · 2020Review
- Therapeutic challenges in the treatment of systemic inflammatory disease in pregnancy.Obstetric medicine · 2019Article
- Updated pharmacological management of rheumatoid arthritis for women before, during, and after pregnancy, reflecting recent guidelines.Irish journal of medical science · 2019Review
- Sonography of active rheumatoid arthritis during pregnancy: a case report and literature review.Radiology case reports · 2018Article
- Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients.PloS one · 2018Article
- Parental rheumatoid arthritis and long-term child morbidity: a nationwide cohort study.Annals of the rheumatic diseases · 2016Article
- Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan.Modern rheumatology · 2016Article
- Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.Drug safety · 2016Article
- Second-line therapy with biological drugs in rheumatoid arthritis patients in German rheumatologist practices: a retrospective database analysis.Rheumatology international · 2016Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease of synovial joints, can lead to chronic pain and structural joint damage, as well as other organ involvement, especially if not adequately controlled. Because it can affect women in their reproductive years, care of pregnant women with RA requires a delicate balance of maintaining disease control while limiting potential toxicity to the fetus and neonate. While most women experience a substantial improvement in disease activity during pregnancy, for some women their RA remains active. It can even manifest itself for the first time during pregnancy or early in the post-partum period. Optimizing disease control prior to conception is key, but utilizing disease-modifying treatments effectively and safely throughout pregnancy and lactation requires open dialogue and shared decision making. This review provides evidence-based recommendations for use of disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers to guide rheumatologists in their care of pregnant and lactating women with RA and serves as a guide to counsel male patients with RA on family planning decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.